Semaglutide for Heart Failure With Preserved Ejection Fraction: Emerging Role

Review of semaglutide emerging role in HFpEF covers STEP-HFpEF trial evidence, mechanisms of benefit, and clinical implementation for heart failure with preserved function.

Arty, Fnu et al.·Cureus·2025·Strong EvidenceReview
RPEP-09991ReviewStrong Evidence2025RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Review
Evidence
Strong Evidence
Sample
N=N/A
Participants
Patients with heart failure with preserved ejection fraction (HFpEF), particularly those with obesity and/or type 2 diabetes

What This Study Found

Review of semaglutide emerging role in HFpEF covers STEP-HFpEF trial evidence, mechanisms of benefit, and clinical implementation for heart failure with preserved function.

Key Numbers

Trials reviewed: SUSTAIN 6, PIONEER 6, STEP HFpEF, STEP HFpEF DM. Focus on obesity-related HFpEF.

How They Did This

In publication.

Why This Research Matters

Relevant to peptide therapeutics.

The Bigger Picture

Advances peptide evidence.

What This Study Doesn't Tell Us

In publication.

Questions This Raises

  • ?Long-term implications?
  • ?Evidence comparison?
  • ?Next steps?

Trust & Context

Key Stat:
Key finding Review of semaglutide emerging role in HFpEF covers STEP-HFpEF trial evidence, mechanisms of benefit
Evidence Grade:
Based on design.
Study Age:
Published in 2025.
Original Title:
Semaglutide in Heart Failure With Preserved Ejection Fraction: Emerging Evidence and Clinical Implications.
Published In:
Cureus, 17(7), e87605 (2025)
Database ID:
RPEP-09991

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study

Summarizes existing research on a topic.

What do these levels mean? →

Frequently Asked Questions

What does this mean?

Review of semaglutide emerging role in HFpEF covers STEP-HFpEF trial evidence, mechanisms of benefit, and clinical implementation for heart failure with preserved function.

How reliable?

Consult publication.

Read More on RethinkPeptides

Cite This Study

RPEP-09991·https://rethinkpeptides.com/research/RPEP-09991

APA

Arty, Fnu; Shreya, Devarashetty; Chaudhry, Aleeza; Sohini, Sarkar. (2025). Semaglutide in Heart Failure With Preserved Ejection Fraction: Emerging Evidence and Clinical Implications.. Cureus, 17(7), e87605. https://doi.org/10.7759/cureus.87605

MLA

Arty, Fnu, et al. "Semaglutide in Heart Failure With Preserved Ejection Fraction: Emerging Evidence and Clinical Implications.." Cureus, 2025. https://doi.org/10.7759/cureus.87605

RethinkPeptides

RethinkPeptides Research Database. "Semaglutide in Heart Failure With Preserved Ejection Fractio..." RPEP-09991. Retrieved from https://rethinkpeptides.com/research/arty-2025-semaglutide-in-heart-failure

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.